SCHEMBL6900928

SCHEMBL6900928

OC[C@H]1OC(O[C@H]2[C@H](O)[C@@H](O)[CH]O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ LGALS8 O00214 1/20 0.49
▸ LGALS3 P17931 1/20 0.49
▸ LGALS4 P56470 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ GJA1 P17302 1/20 0.45
▸ GJB2 P29033 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ LMNA P02545 1/20 0.44
▸ TYR P14679 3/20 0.44
▸ PTPN1 P18031 2/20 0.43
▸ AMY2A P04746 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2139671 1.00 MEN1 (0.50) MEN1KMT2ALGALS8LGALS3LGALS4
SCHEMBL2139680 1.00 MEN1 (0.50) MEN1KMT2ALGALS8LGALS3LGALS4
SCHEMBL3188633 1.00 MEN1 (0.50) MEN1KMT2ALGALS8LGALS3LGALS4
SCHEMBL1389240 1.00 MEN1 (0.50) MEN1KMT2ALGALS8LGALS3LGALS4
SCHEMBL15136505 0.97 LGALS8 (0.53) MEN1KMT2ALGALS8LGALS3LGALS4
SCHEMBL16004719 0.88 MEN1 (0.50) MEN1KMT2ALGALS8LGALS3LGALS4
SCHEMBL7121167 0.88 MEN1 (0.50) MEN1KMT2ALGALS8LGALS3LGALS4
SCHEMBL5971913 0.88 MEN1 (0.50) MEN1KMT2ALGALS8LGALS3LGALS4
SCHEMBL15844865 0.87 AMY1A (0.52) MEN1KMT2ALGALS8LGALS3LGALS4
SCHEMBL11776786 0.85 LMNA (0.55) MEN1KMT2AGJA1GJB2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1381361-A1 COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND PPAR MODULATORS Ortho McNeil Pharmaceutical, Inc. (US) 2004-01-21 — — EP claimed
WO-2002080936-A1 COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND PPAR MODULATORS ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2002-10-17 — — WO claimed
Send feedback